Alopecia Areata Associated with Abacavir Therapy.
- Author:
Hee Sung KIM
1
;
Hyoung Shik SHIN
Author Information
- Publication Type:Brief Communication
- Keywords: Abacavir; Alopecia; Adverse drug reaction
- MeSH: Alopecia; Alopecia Areata*; Drug-Related Side Effects and Adverse Reactions; Exanthema; Fatigue; Hair; Headache; HIV Infections; Humans; Hypersensitivity; Indinavir; Mass Screening; Nausea; Opportunistic Infections; Syphilis; Zidovudine
- From:Infection and Chemotherapy 2014;46(2):103-105
- CountryRepublic of Korea
- Language:English
- Abstract: Abacavir is a nucleoside reverse-transcriptase inhibitor that has been approved for use in combination with other retroviral agents in the treatment of HIV infection. Common adverse reactions include headache, fatigue, nausea, and rash. A fatal hypersensitivity reaction may occur in 5% of patients receiving abacavir; therefore, screening for HLA-B5701 should be performed before starting abacavir. Alopecia areata (AA) is infrequently reported in HIV-infected patients. Certain underlying conditions have been associated with AA, including a decreased CD4:CD8 ratio related to the progression of HIV infection, some opportunistic infections, and syphilis. Several antiretroviral drugs, such as zidovudine, indinavir, indinavir/ritonavir, lopinavir/ritonavir, and atazanavir/ritonavir have been implicated in the development of AA. At present, the occurrence of AA has not been associated with abacavir use. We cannot exclude that the use of abacavir and the development of AA could be coincidental. Nevertheless, patients given abacavir should be monitored for hair loss and the drug discontinued promptly if such signs appear.
